title: Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
authors.affiliation: *The Thoracic Cancer Research and Detection Center, †The Radiation Institute, Sheba Medical Center, Tel Aviv University, Tel-Aviv, Israel; and ‡University of Colorado Cancer Center, Division of Medical Oncology, University of Colorado Denver, Aurora, Colorado.
authors.forename: Nir
authors.initials: N
authors.lastname: Peled
authors.forename: Leor
authors.initials: L
authors.lastname: Zach
authors.forename: Ori
authors.initials: O
authors.lastname: Liran
authors.forename: Maya
authors.initials: M
authors.lastname: Ilouze
authors.forename: Paul A
authors.initials: PA
authors.lastname: Bunn
authors.forename: Fred R
authors.initials: FR
authors.lastname: Hirsch
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000077547:Crizotinib; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*
chemical_list: D004273:DNA, Neoplasm; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases